Long-term efficacy of abatacept in pediatric patients with idiopathic uveitis: a case series

Edoardo Marrani (Corresponding Author), Valeria Paganelli, Cinzia de Libero, Rolando Cimaz, Gabriele Simonini

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

BACKGROUND: Non-infectious uveitis represents one of the most common causes of blindness, even at pediatric age; in particular, idiopathic chronic uveitis can pose significant difficulties during treatment, due to a partial response to TNF-α antagonists. To date, very few case series exist describing the treatment of idiopathic uveitis not adequately controlled by TNF-α antagonists. The aim of our study is to describe the role of abatacept in achieving remission in patients with idiopathic uveitis previously treated with TNF-α antagonists, and to assess how long abatacept efficacy is maintained during follow-up. The treatment's safety profile and tolerability were also specifically investigated.

METHODS: Three patients affected with chronic idiopathic uveitis, who have been treated with abatacept due to loss of efficacy of TNF-α antagonists, were reviewed. Details of the demographic and clinical characteristics were recorded, and a summary of the medical history was obtained. Patients were regularly reviewed in the ophthalmology and rheumatology clinics. Assessment of their ocular condition was characterized according to the Standardization of Uveitis Nomenclature (SUN) group.

RESULTS: In our patients, abatacept was able to induce remission and to discontinue systemic corticosteroids after a mean of 30 weeks; the drug maintained its efficacy through a long follow-up period (42, 33, and 18 months respectively), with an excellent safety profile.

CONCLUSION: Our small case series seems to suggest abatacept to be a promising therapy in children affected with chronic idiopathic uveitis not adequately controlled by TNF-α antagonists.

Original languageEnglish
Pages (from-to)1813-1816
Number of pages4
JournalGraefe's Archive for Clinical and Experimental Ophthalmology
Volume253
Issue number10
Early online date27 Aug 2015
DOIs
Publication statusPublished - Oct 2015

Fingerprint

Uveitis
Pediatrics
Safety
Rheumatology
Ophthalmology
Blindness
Therapeutics
Abatacept
Terminology
Adrenal Cortex Hormones
Demography
Pharmaceutical Preparations

Keywords

  • Abatacept
  • Adolescent
  • Chronic Disease
  • Drug Combinations
  • Female
  • Follow-Up Studies
  • Glucocorticoids
  • Humans
  • Immunosuppressive Agents
  • Male
  • Methotrexate
  • Treatment Outcome
  • Tumor Necrosis Factor-alpha
  • Uveitis
  • Young Adult
  • Case Reports
  • Journal Article

Cite this

Long-term efficacy of abatacept in pediatric patients with idiopathic uveitis : a case series. / Marrani, Edoardo (Corresponding Author); Paganelli, Valeria; de Libero, Cinzia; Cimaz, Rolando; Simonini, Gabriele.

In: Graefe's Archive for Clinical and Experimental Ophthalmology, Vol. 253, No. 10, 10.2015, p. 1813-1816.

Research output: Contribution to journalArticle

Marrani, Edoardo ; Paganelli, Valeria ; de Libero, Cinzia ; Cimaz, Rolando ; Simonini, Gabriele. / Long-term efficacy of abatacept in pediatric patients with idiopathic uveitis : a case series. In: Graefe's Archive for Clinical and Experimental Ophthalmology. 2015 ; Vol. 253, No. 10. pp. 1813-1816.
@article{a6d881ab8abc48f59a755f25deb6a90b,
title = "Long-term efficacy of abatacept in pediatric patients with idiopathic uveitis: a case series",
abstract = "BACKGROUND: Non-infectious uveitis represents one of the most common causes of blindness, even at pediatric age; in particular, idiopathic chronic uveitis can pose significant difficulties during treatment, due to a partial response to TNF-α antagonists. To date, very few case series exist describing the treatment of idiopathic uveitis not adequately controlled by TNF-α antagonists. The aim of our study is to describe the role of abatacept in achieving remission in patients with idiopathic uveitis previously treated with TNF-α antagonists, and to assess how long abatacept efficacy is maintained during follow-up. The treatment's safety profile and tolerability were also specifically investigated.METHODS: Three patients affected with chronic idiopathic uveitis, who have been treated with abatacept due to loss of efficacy of TNF-α antagonists, were reviewed. Details of the demographic and clinical characteristics were recorded, and a summary of the medical history was obtained. Patients were regularly reviewed in the ophthalmology and rheumatology clinics. Assessment of their ocular condition was characterized according to the Standardization of Uveitis Nomenclature (SUN) group.RESULTS: In our patients, abatacept was able to induce remission and to discontinue systemic corticosteroids after a mean of 30 weeks; the drug maintained its efficacy through a long follow-up period (42, 33, and 18 months respectively), with an excellent safety profile.CONCLUSION: Our small case series seems to suggest abatacept to be a promising therapy in children affected with chronic idiopathic uveitis not adequately controlled by TNF-α antagonists.",
keywords = "Abatacept, Adolescent, Chronic Disease, Drug Combinations, Female, Follow-Up Studies, Glucocorticoids, Humans, Immunosuppressive Agents, Male, Methotrexate, Treatment Outcome, Tumor Necrosis Factor-alpha, Uveitis, Young Adult, Case Reports, Journal Article",
author = "Edoardo Marrani and Valeria Paganelli and {de Libero}, Cinzia and Rolando Cimaz and Gabriele Simonini",
note = "Acknowledgments We thanks Dr Roberto Caputo, Head of the Ophthalmology Department in Anna Meyer Children Hospital, for critically reviewing the manuscript.",
year = "2015",
month = "10",
doi = "10.1007/s00417-015-3140-x",
language = "English",
volume = "253",
pages = "1813--1816",
journal = "Graefe's Archive for Clinical and Experimental Ophthalmology",
issn = "0721-832X",
publisher = "Springer Verlag",
number = "10",

}

TY - JOUR

T1 - Long-term efficacy of abatacept in pediatric patients with idiopathic uveitis

T2 - a case series

AU - Marrani, Edoardo

AU - Paganelli, Valeria

AU - de Libero, Cinzia

AU - Cimaz, Rolando

AU - Simonini, Gabriele

N1 - Acknowledgments We thanks Dr Roberto Caputo, Head of the Ophthalmology Department in Anna Meyer Children Hospital, for critically reviewing the manuscript.

PY - 2015/10

Y1 - 2015/10

N2 - BACKGROUND: Non-infectious uveitis represents one of the most common causes of blindness, even at pediatric age; in particular, idiopathic chronic uveitis can pose significant difficulties during treatment, due to a partial response to TNF-α antagonists. To date, very few case series exist describing the treatment of idiopathic uveitis not adequately controlled by TNF-α antagonists. The aim of our study is to describe the role of abatacept in achieving remission in patients with idiopathic uveitis previously treated with TNF-α antagonists, and to assess how long abatacept efficacy is maintained during follow-up. The treatment's safety profile and tolerability were also specifically investigated.METHODS: Three patients affected with chronic idiopathic uveitis, who have been treated with abatacept due to loss of efficacy of TNF-α antagonists, were reviewed. Details of the demographic and clinical characteristics were recorded, and a summary of the medical history was obtained. Patients were regularly reviewed in the ophthalmology and rheumatology clinics. Assessment of their ocular condition was characterized according to the Standardization of Uveitis Nomenclature (SUN) group.RESULTS: In our patients, abatacept was able to induce remission and to discontinue systemic corticosteroids after a mean of 30 weeks; the drug maintained its efficacy through a long follow-up period (42, 33, and 18 months respectively), with an excellent safety profile.CONCLUSION: Our small case series seems to suggest abatacept to be a promising therapy in children affected with chronic idiopathic uveitis not adequately controlled by TNF-α antagonists.

AB - BACKGROUND: Non-infectious uveitis represents one of the most common causes of blindness, even at pediatric age; in particular, idiopathic chronic uveitis can pose significant difficulties during treatment, due to a partial response to TNF-α antagonists. To date, very few case series exist describing the treatment of idiopathic uveitis not adequately controlled by TNF-α antagonists. The aim of our study is to describe the role of abatacept in achieving remission in patients with idiopathic uveitis previously treated with TNF-α antagonists, and to assess how long abatacept efficacy is maintained during follow-up. The treatment's safety profile and tolerability were also specifically investigated.METHODS: Three patients affected with chronic idiopathic uveitis, who have been treated with abatacept due to loss of efficacy of TNF-α antagonists, were reviewed. Details of the demographic and clinical characteristics were recorded, and a summary of the medical history was obtained. Patients were regularly reviewed in the ophthalmology and rheumatology clinics. Assessment of their ocular condition was characterized according to the Standardization of Uveitis Nomenclature (SUN) group.RESULTS: In our patients, abatacept was able to induce remission and to discontinue systemic corticosteroids after a mean of 30 weeks; the drug maintained its efficacy through a long follow-up period (42, 33, and 18 months respectively), with an excellent safety profile.CONCLUSION: Our small case series seems to suggest abatacept to be a promising therapy in children affected with chronic idiopathic uveitis not adequately controlled by TNF-α antagonists.

KW - Abatacept

KW - Adolescent

KW - Chronic Disease

KW - Drug Combinations

KW - Female

KW - Follow-Up Studies

KW - Glucocorticoids

KW - Humans

KW - Immunosuppressive Agents

KW - Male

KW - Methotrexate

KW - Treatment Outcome

KW - Tumor Necrosis Factor-alpha

KW - Uveitis

KW - Young Adult

KW - Case Reports

KW - Journal Article

U2 - 10.1007/s00417-015-3140-x

DO - 10.1007/s00417-015-3140-x

M3 - Article

C2 - 26311261

VL - 253

SP - 1813

EP - 1816

JO - Graefe's Archive for Clinical and Experimental Ophthalmology

JF - Graefe's Archive for Clinical and Experimental Ophthalmology

SN - 0721-832X

IS - 10

ER -